New treatment plans based on CTCL genetic type
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cutaneous T-cell lymphoma (CTCL) that didn't get better with skin treatments (like creams, light therapy, or nitrogen mustard).
- You are between 18 and 75 years old.
- Your doctor expects you to live at least 3 more months.
- You haven't had any other cancer treatment (besides skin treatments) in the past month.
- You don't have another cancer that you're still treating.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for people with a specific type of skin lymphoma. Brentuximab vedotin targets a protein called CD30 on lymphoma cells, and lisaftoclax helps destroy those cells. The goal is to see if this combination is safe and effective.
This trial looks at the results of different systemic (whole-body) treatments for cutaneous T-cell lymphoma (CTCL), a rare type of lymphoma that affects the skin. It aims to understand how well these therapies work and help guide future treatment choices.
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
Hear when a new Cutaneous T-Cell Lymphoma/Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.